Tislelizumab Plus Platinum and Etoposide as a First-Line Treatment for Extensive-Stage SCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
J Thorac Oncol 2024 Mar 07;[EPub Ahead of Print], Y Cheng, Y Fan, Y Zhao, D Huang, X Li, P Zhang, M Kang, N Yang, D Zhong, Z Wang, Y Yu, Y Zhang, J Zhao, T Qin, C Chen, S Leaw, W Zheng, Y SongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.